Reason for request
Reassessment
Summary of opinion
Favourable opinion for reimbursement in the treatment of HIV-1 infection only in adults and adolescents above 12 years of age weighing at least 40 kg:
- who are treatment-naive, with a CD4 count of more than 200/mm3, a viral load (VL) of less than 500,000 copies/mL and with no known or suspected resistance to either of the two drugs;
- previously treated, with a stable VL < 50 copies/mL for at least one year, a CD4 count of more than 350/mm3 and with no known or suspected resistance to either of the two drugs.
Unfavourable opinion for reimbursement in the other situations covered by the MA indication.
Clinical Benefit
| Substantial |
The clinical benefit of DOVATO (dolutegravir/lamivudine) is substantial only in adults and adolescents above 12 years of age
weighing at least 40 kg:
- who are treatment-naive, with a CD4 count of more than 200/mm3, a viral load (VL) of less than 500,000 copies/mL and with no known or suspected resistance to either of the two drugs;
- previously treated, with a stable VL < 50 copies/mL for at least one year, a CD4 count of more than 350/mm3 and with no known or suspected resistance to either of the two drugs.
|
| Insufficient |
The clinical benefit is insufficient to justify public funding cover in the other populations of the MA. |
Clinical Added Value
| minor |
Updating of the reimbursement scope in view of the long-term follow-up data from the GEMINI 1 and 2 studies and in line with current HAS recommendations, does not modify the clinical added value level of DOVATO (dolutegravir/lamivudine) according to the opinion of 8 January 2020:
- minor clinical added value (CAV IV) in the treatment of HIV-1 infection in adults and adolescents above 12 years of age who are treatment-naive, with a CD4 count of more than 200/mm3, a VL of < 500,000 copies/mL and with no known or suspected resistance to either of the two drugs,
- no clinical added value (CAV V) in the treatment of patients infected with HIV-1, who are previously treated and virologically suppressed, compared to the proprietary medicinal product JULUCA.
|
| no clinical added value |
Updating of the reimbursement scope in view of the long-term follow-up data from the GEMINI 1 and 2 studies and in line with current HAS recommendations, does not modify the clinical added value level of DOVATO (dolutegravir/lamivudine) according to the opinion of 8 January 2020:
- minor clinical added value (CAV IV) in the treatment of HIV-1 infection in adults and adolescents above 12 years of age who are treatment-naive, with a CD4 count of more than 200/mm3, a VL of < 500,000 copies/mL and with no known or suspected resistance to either of the two drugs,
- no clinical added value (CAV V) in the treatment of patients infected with HIV-1, who are previously treated and virologically suppressed, compared to the proprietary medicinal product JULUCA.
|
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
Qhqam0bTdzeJEcC0
